Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, Domainex Partner on Epigenetics

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – UK Contract research organization Domainex and Sigma-Aldrich today announced a collaboration to develop tools for epigenetic research.

Under the deal, Domainex will use its proprietary Combinatorial Domain Hunting technology to clone and express proteins to build biochemical assays for target enzymes. The technology, the company said in a statement, allows researchers to clone and express challenging proteins, producing soluble domains of proteins with key roles in epigenetics.

Sigma-Aldrich will use the proteins as antigens to raise specific monoclonal antibodies. It will also distribute the assays and monoclonal antibodies, which scientists can use to identify target proteins, and then characterize and study their functions in detail.

Funding from the UK's Technology Strategy Board will support the work. Financial and other terms were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.